KLF5 and ovarian cancer: Moreover, administration of A2780-olaR and SKOV3-olaR with ML264 for KLF5 inhibition resulted in a reduction in the sphere-forming ability of ovarian cancer cells (Fig. 3E and G).Flow cytometry analysis revealed a significant reduction in the proportion of ALDH positive cells in ovarian cancer cells treated with ML264 (Fig. 3F and H).